Basilea reports positive Phase III antibiotic data

A late-stage trial of the experimental antibiotic ceftobiprole, which is being jointly developed by Basilea and J&J, has demonstrated significant results, with 86 percent of patients being cured of diabetic foot infections. The therapy, which is under review at the FDA, also demonstrated signs of success against antibiotic-resistant bacteria, or Staphylococcus aureus. Researchers unveiled the data at the Infectious Disease Society of America meeting in San Diego.

"Diabetic foot infections are becoming increasingly difficult to treat," said study author, Gary J. Noel, M.D., with Johnson & Johnson Pharmaceutical Research & Development. "These data suggest that ceftobiprole may be useful as stand-alone therapy for this increasingly common type of complicated skin infection."

- check out the release for more info

Related Articles:
Basilea shares jump on antibiotic data. Report
Basilea gets fast track for antifungal drug. Report
MRSA-CA danger to healthcare workers. Report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.